12:00 AM
 | 
Dec 17, 2012
 |  BC Week In Review  |  Company News  |  Other News

Hologic, KV Pharmaceutical genitourinary news

KV will pay Hologic $60 million by year end to settle all claims related to preterm birth drug Makena hydroxyprogesterone caproate. KV, which has rights to the long-acting 17p from Hologic, filed for Chapter 11 bankruptcy in August. Hologic subsequently filed a claim against KV in bankruptcy court for...

Read the full 235 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >